ReviewInflammation2026
P300 in Inflammation: An Updated Perspective on Its Molecular Mechanisms and Therapeutic Potential.
Review in Inflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Transcription cofactor p300 is characterized by histone acetyltransferase (HAT) activity, which endows p300 with dual functions of chromatin remodeling and gene transcription and participates in regulating various basic cellular functions. P300 mainly enhances the expression of downstream pro-inflammatory factors such as TNF-α and IL-6 by acetylating core transcription factors in the inflammatory signaling pathway, such as NF-κB and JAK/STAT. P300 also reshapes the epigenetic profile of important cellular components in inflammation, such as macrophages or T cells, by mediating histone H3K27ac modification. Based on the above molecular mechanisms, p300 plays a key role in various inflammatory diseases, including respiratory inflammatory, autoimmune, metabolic-related and neuroinflammatory diseases as well as infectious inflammation. Small molecule inhibitors targeting p300 show anti-inflammatory potential in various preclinical animal models; however, their tissue-specific targeting mechanisms and long-term safety need further exploration. The current review summarizes the molecular mechanism basis, cell specific functions, and targeted intervention strategies of p300 in inflammatory diseases, and explores the development of novel p300-based anti-inflammatory medication.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.